QIAGEN/$QGEN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About QIAGEN
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
Ticker
$QGEN
Sector
Primary listing
NYSE
Industry
Life Sciences Tools & Services
Headquarters
Employees
5,700
ISIN
NL0015002CX3
Website
QIAGEN Metrics
BasicAdvanced
$10B
110.70
$0.42
0.67
-
0.54%
Price and volume
Market cap
$10B
Beta
0.67
52-week high
$47.70
52-week low
$37.63
Average daily volume
1.5M
Financial strength
Current ratio
3.371
Quick ratio
2.568
Long term debt to equity
39.692
Total debt to equity
41.326
Interest coverage (TTM)
12.87%
Profitability
EBITDA (TTM)
701.721
Gross margin (TTM)
66.90%
Net profit margin (TTM)
4.68%
Operating margin (TTM)
26.25%
Effective tax rate (TTM)
32.32%
Revenue per employee (TTM)
$350,000
Management effectiveness
Return on assets (TTM)
5.75%
Return on equity (TTM)
2.67%
Valuation
Price to earnings (TTM)
110.701
Price to revenue (TTM)
5.035
Price to book
2.96
Price to tangible book (TTM)
15.07
Price to free cash flow (TTM)
20.045
Free cash flow yield (TTM)
4.99%
Free cash flow per share (TTM)
232.23%
Forward dividend yield
0.54%
Growth
Revenue change (TTM)
3.31%
Earnings per share change (TTM)
-72.82%
3-year revenue growth (CAGR)
-4.68%
10-year revenue growth (CAGR)
4.21%
3-year earnings per share growth (CAGR)
-45.27%
10-year earnings per share growth (CAGR)
-1.86%
Bulls say / Bears say
QIAGEN's recent collaboration with Mirati Therapeutics to develop a KRASG12C companion diagnostic for non-small cell lung cancer (NSCLC) positions the company at the forefront of precision medicine, potentially expanding its market share in oncology diagnostics. (businesswire.com)
The FDA's clearance of QIAGEN's second QIAstat-Dx mini gastrointestinal panel enhances its syndromic testing portfolio in the U.S., likely driving increased adoption and revenue growth. (businesswire.com)
Analysts from Robert W. Baird and JPMorgan Chase & Co. have raised their price targets for QIAGEN to $52 and $54 respectively, reflecting confidence in the company's growth prospects. (marketbeat.com)
Despite a 0.66% increase in revenue to $1.98 billion in 2024, QIAGEN's earnings decreased by 75.51% to $83.59 million, indicating potential profitability challenges. (stockanalysis.com)
The company's net income for Q4 2024 declined by 9.57% year-over-year to $88.32 million, suggesting ongoing financial pressures. (google.com)
Morgan Stanley downgraded QIAGEN to 'Hold' from 'Buy' on January 6, 2025, citing concerns over decelerating tuberculosis test growth and emerging competition. (tipranks.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
QIAGEN News
AllArticlesVideos
Qiagen and Gencurix Enter Clinical Diagnostics Partnership
Market Watch·2 days ago
QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership
Business Wire·2 days ago
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
Business Wire·5 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Jul2
QIAGEN
Dividend·Ex-dividend
Jul10
QIAGEN
Dividend·Payment
$0.25Per share
FAQs
What’s the current market cap for QIAGEN stock?
QIAGEN (QGEN) has a market cap of $10B as of June 20, 2025.
What is the P/E ratio for QIAGEN stock?
The price to earnings (P/E) ratio for QIAGEN (QGEN) stock is 110.7 as of June 20, 2025.
Does QIAGEN stock pay dividends?
No, QIAGEN (QGEN) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next QIAGEN dividend payment date?
QIAGEN (QGEN) stock does not pay dividends to its shareholders.
What is the beta indicator for QIAGEN?
QIAGEN (QGEN) has a beta rating of 0.67. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.